📰 Michael Kaiser News
Page 7 - Michael Kaiser News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Kaiser. Real-time updates on events, politics, business and more.
January 29, 2024
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development...
January 29, 2024
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...
January 17, 2024
On Monday, Jan. 15, the Fergus Falls Police Department and Otter Tail County Sheriff’s Office responded to threatening calls in Fergus Falls, Minnesota. The calls were made to the public
January 16, 2024
NEW YORK and VIENNA, Austria, Jan. 16, 2024 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the...
January 12, 2024
Canyon has announced that Chad Manuell will join the brand as chief technology officer. The move will help deepen Canyon’s consumer-led growth and - BikeBiz
January 11, 2024
With an 8-0 vote Wednesday, Jan. 10, the Wahpeton School Board approved hiring Steve Hockert as principal of Wahpeton High School beginning in the 2024-2025 education year. The vote also
December 21, 2023
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s...
December 18, 2023
Officer Lisa Page, Wahpeton Police Department, serves as Wahpeton Public School District’s Resource Officer (RO). Resource officers are the individuals inside schools to ensure everyones safety. Resource officers are not
November 18, 2023
More than half of Americans between the ages of 16-74 read below a sixth grade level. Out of nearly 200 countries in terms of literacy rate, measured by the age
November 9, 2023
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected to start in 2024 Published peer-reviewed preclinical data, in collaboration with Gilead Sciences, for HB-400 program in The Journal of Infectious Disease Recruitment ongoing for two Phase 1 clinical trials